Relative systemic availability of budesonide in patients with asthma after inhalation from two dry powder inhalers

Current Medical Research and Opinion

Volumn 24, Issue 5, 2008, Pages 1511-1517

  Persson, Gunnar ^a   Ankerst, Jaro ^a   Gillen, Michael ^b   Bengtsson, Thomas ^c   Thorsson, Lars ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Bioequivalence; Budesonide; Dry powder inhaler; Inhaled corticosteroids; Pharmacokinetics

Indexed keywords

BUDESONIDE;

AGED; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRY POWDER; FEMALE; HUMAN; INHALER; MALE; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 44349158930     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X297312     Document Type: Article

References (18)

1. Banov CH. The role of budesonide in adults and children with mild-to-moderate persistent asthma. J Asthma 2004;41:5-17
2. Selroos O, Edsbäcker S, Hultquist C. Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation. J Asthma 2004;41:771-90
3. Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998;101:457-63
4. Shapiro G, Bronsky EA, LaForce CF, et al. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr 1998;132:976-82
5. Kemp J, Wanderer AA, Ramsdell J, et al. Rapid onset of control with budesonide Turbuhaler in patients with mild-to-moderate asthma. Ann Allergy Asthma Immunol 1999;82:463-71
6. Nelson HS, Bernstein IL, Fink J, et al., for the Pulmicort Turbuhaler Study Group. Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler: a double-blind, placebo-controlled study in adults with moderate-to-severe chronic asthma. Chest 1998;113:1264-71
7. McFadden ER, Casale TB, Edwards TB, et al. Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. J Allergy Clin Immunol 1999;104:46-52
8. Shapiro GG, Mendelson LM, Pearlman DS. Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids. Ann Allergy Asthma Immunol 2001;86:633-40
9. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma. Full Report 2007. August 2007. NHLBI publication no. 08-4051
10. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda (MD): National Institutes of Health, National Heart, Lung, and Blood Institute 2007: Available at: http://www.ginasthma.org
11. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005;127:335-71
12. Olsson B, Asking L. Critical aspects of the function of inspiratory flow driven inhalers. J Aersol Med 1994;7(Suppl 1) S43-7
13. Fink JB. Metered-dose inhalers, dry powder inhalers, and transitions. Respir Care 2000;45:623-35
14. Pulmicort Turbuhaler 200 μg [package insert]. Wilmington, DE: AstraZeneca LP, 2006
15. Pulmicort Flexhaler 90 μg and 180 μg [package insert]. Wilmington, DE: AstraZeneca LP, 2006
16. Kerwin EM, Pearlman DS, de Guia T, et al. Evaluation of efficacy, safety, and pharmacokinetics of budesonide delivered via two dry powder inhalers. Curr Med Res Opin 2008;4:1497-510
17. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-44
18. Borgström L, Olsson B, Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med 2006;19:473-83